Home
/
NEUROCRINE BIOSCIENCES INC
/
Financials
/
Quarterly
NEUROCRINE BIOSCIENCES INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that NEUROCRINE BIOSCIENCES INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2018
Jun 30, 2018
$96.91M
Jul 31, 2018
Q1
2018
Mar 31, 2018
$71.09M
Apr 30, 2018
Q3
2017
Sep 30, 2017
$60.77M
Nov 1, 2017
Q2
2018
Jun 30, 2017
$6.34M
Jul 31, 2018
Q1
2018
Mar 31, 2017
$0
Apr 30, 2018
Q3
2017
Sep 30, 2016
$0
Nov 1, 2017
Q2
2017
Jun 30, 2016
$0
Aug 3, 2017
Q1
2017
Mar 31, 2016
$15.00M
May 9, 2017
Q3
2016
Sep 30, 2015
$0
Nov 2, 2016
Q2
2016
Jun 30, 2015
$0
Aug 3, 2016
Q1
2016
Mar 31, 2015
$19.77M
May 5, 2016
Q3
2015
Sep 30, 2014
$0
Oct 29, 2015
Q2
2015
Jun 30, 2014
$0
Jul 29, 2015
Q1
2015
Mar 31, 2014
$0
Apr 30, 2015
Q3
2014
Sep 30, 2013
$729.0K
Nov 4, 2014
Q2
2014
Jun 30, 2013
$730.0K
Aug 6, 2014
Q1
2014
Mar 31, 2013
$730.0K
May 1, 2014
Q3
2013
Sep 30, 2012
$9.36M
Oct 29, 2013
Q2
2013
Jun 30, 2012
$10.57M
Jul 26, 2013
Q1
2013
Mar 31, 2012
$11.27M
May 2, 2013
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$794.90M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$687.50M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$572.60M
May 5, 2025
Q3
2025
Sep 30, 2024
$622.10M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$590.20M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$515.30M
May 5, 2025
Q3
2024
Sep 30, 2023
$498.80M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$452.70M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$420.40M
May 1, 2024
Q3
2023
Sep 30, 2022
$387.90M
Oct 31, 2023
Q2
2023
Jun 30, 2022
$378.20M
Aug 1, 2023
Q1
2023
Mar 31, 2022
$310.60M
May 3, 2023
Q3
2022
Sep 30, 2021
$296.00M
Nov 1, 2022
Q2
2022
Jun 30, 2021
$288.90M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$236.60M
May 4, 2022
Q3
2021
Sep 30, 2020
$258.50M
Nov 1, 2021
Q2
2021
Jun 30, 2020
$302.40M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$237.10M
May 5, 2021
Q3
2020
Sep 30, 2019
$222.10M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$183.50M
Aug 3, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$209.50M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$107.50M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$7.90M
May 5, 2025
Q3
2025
Sep 30, 2024
$129.80M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$65.00M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$43.40M
May 5, 2025
Q3
2024
Sep 30, 2023
$83.10M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$95.50M
Aug 1, 2024
Q1
2024
Mar 31, 2023
($76.60M)
May 1, 2024
Q3
2023
Sep 30, 2022
$68.50M
Oct 31, 2023
Q2
2023
Jun 30, 2022
($16.90M)
Aug 1, 2023
Q1
2023
Mar 31, 2022
$13.90M
May 3, 2023
Q3
2022
Sep 30, 2021
$22.50M
Nov 1, 2022
Q2
2022
Jun 30, 2021
$42.30M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$32.10M
May 4, 2022
Q3
2021
Sep 30, 2020
($57.60M)
Nov 1, 2021
Q2
2021
Jun 30, 2020
$79.60M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$37.40M
May 5, 2021
Q3
2020
Sep 30, 2019
$53.80M
Nov 9, 2020
Q3
2019
Jun 30, 2019
$51.34M
Nov 4, 2019
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$239.00M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$145.60M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$23.60M
May 5, 2025
Q3
2025
Sep 30, 2024
$183.80M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$145.40M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$99.30M
May 5, 2025
Q3
2024
Sep 30, 2023
$141.20M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$73.60M
Aug 1, 2024
Q1
2024
Mar 31, 2023
($114.20M)
May 1, 2024
Q3
2023
Sep 30, 2022
$87.80M
Oct 31, 2023
Q2
2023
Jun 30, 2022
$54.70M
Aug 1, 2023
Q1
2023
Mar 31, 2022
$3.10M
May 3, 2023
Q3
2022
Sep 30, 2021
$44.50M
Nov 1, 2022
Q2
2022
Jun 30, 2021
$62.80M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$31.50M
May 4, 2022
Q3
2021
Sep 30, 2020
($44.30M)
Nov 1, 2021
Q2
2021
Jun 30, 2020
$76.60M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$58.90M
May 5, 2021
Q3
2020
Sep 30, 2019
$90.10M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$34.40M
Aug 3, 2020